Qiagen has announced a significant expansion of its business in the Middle East region, which includes three major developments- In early 2024, the company will open its regional headquarters in Riyadh, Saudi Arabia, in order to further strengthen its commercial footprint in the region. It has signed a Memorandum of Understanding (MoU) with the Ministry of Health of Saudi Arabia, addressing various public health and infection control initiatives. 

The MoU includes establishment a localised data centre by Qiagen Digital Insights (QDI) to support advanced bioinformatics within the country.

Qiagen has been awarded a tender through its Commercial Partner Taiba Medserv LLC from the Ministry of Health of the Sultanate of Oman to provide the country with QuantiFERON-TB Gold Plus tests for its nationwide tuberculosis (TB) screening programme.

As a country with a low incidence of TB and a large workforce from high-incidence countries, Oman is expanding its TB testing policy for residency applicants by adding systematic screening for latent TB infection using Qiagen’s simple standard-setting QuantiFERON-TB Gold Plus blood test. The Ministry of Health plans to test up to 800,000 people over two years and offer direct medical treatment to those found carrying TB bacteria without symptoms.